Heyholder
‹ Activism Filings

EyeGene,Inc Korea approves revised Phase 2/3 trial plan for EGMCV4 meningococcal vaccine

EyeGene,Inc

AI summary · Not investment advice

Regulators approved a revised Phase 2/3 trial plan for EGMCV4, a meningococcal vaccine from Egene, in Korea on November 12, 2026.

Commentary

AI commentary · Not investment advice

What happened

Aigen received approval from Korea's Ministry of Food and Drug Safety (MFDS) to change the plan for its phase 2/3 trial of EGMCV4, a 4-valent meningococcal vaccine. The vaccine aims to prevent invasive meningococcal disease caused by groups A, C, W-135 and Y.

In the company's terms

The trial runs in South Korea at multiple sites, including Eunpyeong St. Mary's Hospital of the Catholic University of Korea. Part 1 is phase 2 with a target of 125 participants. Part 2 is phase 3 with a target of 998 participants, split into Cohort A with 730 and Cohort B with 268. Cohort B has 230 in the test group and 38 in the control group, and it assesses safety only.

What changes for shareholders

The change follows an MFDS request for revisions. The trial title now says double-blind, meaning neither participants nor evaluators know who gets which treatment. To keep Cohort B double-blind, the number of control participants was increased.

The trial period is 30 months from the approval date of the institutional review board. It can be extended depending on how long recruitment takes. The expected end date is 2027.12.31.

Earlier filings of the same type

Filings of the same type
FiledTitleKey figure · Note
26.11.10Nov 10, 2026

Comments

No comments yet

Comments from shareholders will appear here.